Nortriptyline and its hydroxymetabolites in breastfeeding mothers and newborns

Katherine L. Wisner, James M. Perel, Robert L Findling, Robert L. Hinnes

Research output: Contribution to journalArticle

Abstract

We previously reported the serum nortriptyline levels of a series of breastfeeding mother-infant pairs. Nortriptyline was below the level of detectability in the infants' sera; however, two young infants aged 10 weeks or less had low concentrations of 10-hydroxy-nortriptyline. Because very young breastfeeding infants are likely to be at increased risk for toxicity, we have focused our study on breastfeeding newborns. We present additional data from six mothers and their infants (4 weeks of age), as well as data from one prematurely born baby. We were able to quantify nortriptyline in one infant and another had higher levels of hydroxy-metabolites than previously reported, although still very low. No adverse clinical effects were observed in the infants.

Original languageEnglish (US)
Pages (from-to)249-251
Number of pages3
JournalPsychopharmacology Bulletin
Volume33
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

Nortriptyline
Breast Feeding
Mothers
Newborn Infant
Serum

Keywords

  • Breastfeeding
  • Newborn
  • Nortriptyline
  • Nortriptyline 10- hydroxymetabolites
  • Toxicity monitoring

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Nortriptyline and its hydroxymetabolites in breastfeeding mothers and newborns. / Wisner, Katherine L.; Perel, James M.; Findling, Robert L; Hinnes, Robert L.

In: Psychopharmacology Bulletin, Vol. 33, No. 2, 1997, p. 249-251.

Research output: Contribution to journalArticle

Wisner, Katherine L. ; Perel, James M. ; Findling, Robert L ; Hinnes, Robert L. / Nortriptyline and its hydroxymetabolites in breastfeeding mothers and newborns. In: Psychopharmacology Bulletin. 1997 ; Vol. 33, No. 2. pp. 249-251.
@article{ca1628f7b48e4fe1943460ebbb672368,
title = "Nortriptyline and its hydroxymetabolites in breastfeeding mothers and newborns",
abstract = "We previously reported the serum nortriptyline levels of a series of breastfeeding mother-infant pairs. Nortriptyline was below the level of detectability in the infants' sera; however, two young infants aged 10 weeks or less had low concentrations of 10-hydroxy-nortriptyline. Because very young breastfeeding infants are likely to be at increased risk for toxicity, we have focused our study on breastfeeding newborns. We present additional data from six mothers and their infants (4 weeks of age), as well as data from one prematurely born baby. We were able to quantify nortriptyline in one infant and another had higher levels of hydroxy-metabolites than previously reported, although still very low. No adverse clinical effects were observed in the infants.",
keywords = "Breastfeeding, Newborn, Nortriptyline, Nortriptyline 10- hydroxymetabolites, Toxicity monitoring",
author = "Wisner, {Katherine L.} and Perel, {James M.} and Findling, {Robert L} and Hinnes, {Robert L.}",
year = "1997",
language = "English (US)",
volume = "33",
pages = "249--251",
journal = "Psychopharmacology Bulletin",
issn = "0048-5764",
publisher = "MedWorks Media LLC",
number = "2",

}

TY - JOUR

T1 - Nortriptyline and its hydroxymetabolites in breastfeeding mothers and newborns

AU - Wisner, Katherine L.

AU - Perel, James M.

AU - Findling, Robert L

AU - Hinnes, Robert L.

PY - 1997

Y1 - 1997

N2 - We previously reported the serum nortriptyline levels of a series of breastfeeding mother-infant pairs. Nortriptyline was below the level of detectability in the infants' sera; however, two young infants aged 10 weeks or less had low concentrations of 10-hydroxy-nortriptyline. Because very young breastfeeding infants are likely to be at increased risk for toxicity, we have focused our study on breastfeeding newborns. We present additional data from six mothers and their infants (4 weeks of age), as well as data from one prematurely born baby. We were able to quantify nortriptyline in one infant and another had higher levels of hydroxy-metabolites than previously reported, although still very low. No adverse clinical effects were observed in the infants.

AB - We previously reported the serum nortriptyline levels of a series of breastfeeding mother-infant pairs. Nortriptyline was below the level of detectability in the infants' sera; however, two young infants aged 10 weeks or less had low concentrations of 10-hydroxy-nortriptyline. Because very young breastfeeding infants are likely to be at increased risk for toxicity, we have focused our study on breastfeeding newborns. We present additional data from six mothers and their infants (4 weeks of age), as well as data from one prematurely born baby. We were able to quantify nortriptyline in one infant and another had higher levels of hydroxy-metabolites than previously reported, although still very low. No adverse clinical effects were observed in the infants.

KW - Breastfeeding

KW - Newborn

KW - Nortriptyline

KW - Nortriptyline 10- hydroxymetabolites

KW - Toxicity monitoring

UR - http://www.scopus.com/inward/record.url?scp=0030795509&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030795509&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 249

EP - 251

JO - Psychopharmacology Bulletin

JF - Psychopharmacology Bulletin

SN - 0048-5764

IS - 2

ER -